Hypnotics and Sedatives, Prone Position, Pulmonary Ventilation, Severe Acute Respiratory Syndrome Coronavirus 2
Conditions
Keywords
Critical Care, acute respiratory distress syndrome
Brief summary
This study focuses on the evaluation of various factors repeatedly discussed in relation to the impaired sedation of intubated ventilated COVID-19 patients. The sedation response of \>100 moderately to severely affected COVID-19 ARDS was evaluated. The sedation level was measured at the bedside using the Richmond Agitation and Sedation Scale and ventilator synchrony. The evaluation was performed according to the static evaluation plan with respect to age, storage therapy and organ failure.
Interventions
OTHERTreatment group
None, solely treatment documentation
Sponsors
Goethe University
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
moderate to severe COVID-19 ARDS
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient Characteristics | The data is recorded at the time of enrolment | Age (in years) |
| Application of sedative | 30 minutes after study enrolment | Applied dosage of midazolam (measured in mg/kg/h) |
| Change in sedative dosage applied | Change in average dosage within 8 hours. | Applied dosage of midazolam (measured in mg/kg/h) |
| Position therapy | Data collection is performed at the date of death from any cause or discharge up to 10 weeks. | Number of positioning therapys during treatment |
| Agitation and sedation level | 30 minutes after study enrolment | Measurement is performed using the Richmond Agitation and Sedation Scale (RASS, range: -5\[Unarousable\] to +4 \[Combative\], normal condition=0 \[Alert and calm\]) |
| Application of opioid analgesic | 30 minutes after study enrolment | Applied dosage of sufentanil (measured in µg/kg/h) |
| Change of application of opioid analgesic | Change in average dosage within 8 hours. | Applied dosage of sufentanil (measured in µg/kg/h) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Need for extracorporeal membrane oxygenation (vvECMO) | Data collection is performed at the date of death from any cause or discharge up to 10 weeks. | The necessity and application of an extracorporeal oxygenation procedure (ECMO) is documented |
| Need for renal replacement therapy | Data collection is performed at the date of death from any cause or discharge up to 10 weeks. | The necessity and application of a renal replacement procedure is documented |
Countries
Germany
Outcome results
None listed